Capricor (CAPR) Faces Governance Reset Demands and Management Pressure

Activist fund Kaos Capital has strongly urged Capricor Therapeutics (CAPR) to replace its management and freeze non-essential expenditures. This intervention occurred just one day before the FDA's decision on deramiocel, a cell therapy candidate for Duchenne Muscular Dystrophy (DMD). With the advisory committee's rejection of its cardiomyopathy efficacy, a shift in focus to skeletal muscle clinical data and potential label modifications has become inevitable, raising concerns about further approval delays. Kaos is pressuring the company to reduce development risk concentrated in a single asset by establishing a strategic M&A committee.

BMS Collaborates with Chai Discovery to Accelerate AI-Driven Antibody Drug Discovery

Bristol Myers Squibb (BMY) has entered a strategic collaboration with promising startup Chai Discovery to enhance its AI-based drug discovery capabilities. The two companies will leverage Chai's proprietary molecular folding models to rapidly identify antibody candidates targeting previously intractable proteins such as multi-pass transmembrane proteins. Chai Discovery, valued at $3.8 billion, is expanding partnerships with companies like Pfizer. This deal serves as a key piece in BMY's digital transformation strategy, following its collaboration with NVIDIA on AI centers.

Eli Lilly (LLY) Incubates Amplitude Therapeutics and Develops Next-Generation Infectious Disease Vaccines

Eli Lilly (LLY) has launched a collaboration with Amplitude Therapeutics, an incubatee of its in-house Gateway Labs, to develop next-generation infectious disease vaccines. The companies plan to develop trans-amplifying RNA (taRNA) vaccines, which separate the polymerase and antigen coding regions to significantly enhance safety and potency. Lilly holds exclusive global clinical and commercialization rights and has secured additional target options. This move highlights Lilly's strategy to diversify its vaccine pipeline by acquiring infectious disease-focused companies.

Kynexis Advances KYN-5356 into Phase 2 for Schizophrenia-Related Cognitive Impairment

Dutch neuroscience company Kynexis has secured an additional €40 million (totaling €97 million) in Series A financing, led by Novartis Venture Fund. The funding will be fully allocated to complete the Phase 2 trial of KYN-5356, a KAT-II inhibitor being developed as a treatment for cognitive impairment associated with schizophrenia (CIAS). KYN-5356 is the first-in-class drug designed to normalize cognitive function by inhibiting kynurenic acid production in the brain. The industry is closely watching the top-line data from the Phase 2 trial, expected to be released by year-end, given the significant unmet need in the CIAS market.

Network Bio Secures $50 Million Financing and Develops Medical AI Models

Healthcare data startup Network Bio has officially launched following a $50 million funding round led by Section 32. The company plans to collaborate with large hospital biobank networks to build patient tissue and blood datasets and train general-purpose medical AI models. It also aims to accelerate model training using NVIDIA's technology for multi-omics data such as cell-free RNA (cfRNA). Network Bio has already signed a $30 million AI model licensing agreement with a major healthcare company shortly after its launch, demonstrating the strong value of its business model.